


**Product Name** : Belzutifan  
**Cat. No.** : PC-72737  
**CAS No.** : 1672668-24-4  
**Molecular Formula** : C<sub>17</sub>H<sub>12</sub>F<sub>3</sub>NO<sub>4</sub>S  
**Molecular Weight** : 383.341  
**Target** : HIF/HIF Prolyl-hydroxylase  
**Solubility** : 100 mM in DMSO (38.2 mg/mL)



## Biological Activity

Belzutifan (PT2977, MK-6482) is a potent and selective small-molecule inhibitor of **HIF2 $\alpha$**  with SPA IC<sub>50</sub> of 9 nM, EC<sub>50</sub> of 11 nM (HIF-2 $\alpha$  luciferase assay).

PT2977 demonstrated high potency with EC<sub>50</sub> of 17 nM in the VEGFA secretion assay in 786-O cells.

PT2977 (0.3, 1, and 3 mg/kg, oral) potently and dose-dependently reduced mRNA levels of human cyclin D1, a target gene regulated by HIF-2 $\alpha$ , exhibited excellent antitumor activity in the 786-O mouse xenograft model

In phase 1 clinical, PT2977 decreased in the HIF-2 $\alpha$  target erythropoietin (EPO) following once daily oral administration of PT2977 at the dose levels of 20, 40, 80, 120, 160, and 240 mg in patients with solid tumors, also showed encouraging outcomes in patients with advanced renal cell carcinoma in an expansion cohort of 55 patients with ccRCC treated at 120 mg q.d.

## References

Choueiri TK, et al. *Nat Med*. 2021 May;27(5):802-805.

Xu R, et al. *J Med Chem*. 2019 Aug 8;62(15):6876-6893.

Jonasch E, et al. *N Engl J Med*. 2021 Nov 25;385(22):2036-2046.

Kamihara J, et al. *N Engl J Med*. 2021 Nov 25;385(22):2059-2065.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com